Last reviewed · How we verify
Suramin Sodium
Suramin Sodium is a Small molecule drug developed by Paxmedica. It is currently in Phase 2 development. Also known as: Placebo.
Suramin Sodium is being studied in clinical trials for various conditions, including non-small cell lung carcinoma, autism spectrum disorder, brain and central nervous system tumors, acute kidney injury, and adrenocortical carcinoma. The mechanism of action of Suramin Sodium is currently unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Suramin Sodium |
|---|---|
| Also known as | Placebo |
| Sponsor | Paxmedica |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD) (PHASE2)
- Double Blind Trial in Children With Autism Spectrum Disorder (PHASE2)
- A Retrospective Analysis of Suramin Treatment for Stage 1 TBR
- Study of Suramin in Subjects With Furosemide-Resistant AKI (PHASE2)
- Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer (PHASE2)
- University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial (PHASE1, PHASE2)
- Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium (PHASE1)
- Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Suramin Sodium CI brief — competitive landscape report
- Suramin Sodium updates RSS · CI watch RSS
- Paxmedica portfolio CI
Frequently asked questions about Suramin Sodium
What is Suramin Sodium?
Who makes Suramin Sodium?
Is Suramin Sodium also known as anything else?
What development phase is Suramin Sodium in?
Related
- Manufacturer: Paxmedica — full pipeline
- Also known as: Placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing